⌕
Lite Strategy · LITS · Nasdaq
Tenet 57 · Mixed
Compare
$0.86+1.16%At closeTenet 57 · Mixed
$0.86+0.01 (+1.16%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Lite Strategy (LITS) Stock

Lite Strategy (LITS) closed at $0.86 on Nov 16, 2026; its Tenet Score is 57 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$0.86
Nov 16, 2026
Market cap
$25.6M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
206.68%
past year's regular dividends ÷ price
52-week range
0.69 – 2.08
low → high
Tenet Score
57/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Lite Strategy, Inc. scores 57/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 57 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
57/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
98
Quality
5
Health
68
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueA+QualityFHealthCGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.6×
cap ÷ fiscal 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−243%
fiscal 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
5.74
fiscal 2026
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Lite Strategy, Inc.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 3 US ETFs · top wrappers by weightSee all ETFs holding LITS →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Lite Strategy in?

Lite Strategy is in the Healthcare sector and the Drugs industry.

What is Lite Strategy's Tenet Score?

Lite Strategy's Tenet Score is 57 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.